Brokerages Set Genmab A/S (NASDAQ:GMAB) PT at $42.17

Shares of Genmab A/S (NASDAQ:GMAB) have been given an average recommendation of “Moderate Buy” by the thirteen ratings firms that are currently covering the stock, MarketBeat reports. Four research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $41.33.

GMAB has been the subject of a number of recent analyst reports. Leerink Partners upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 target price for the company in a research report on Thursday, February 13th. Sanford C. Bernstein upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, December 20th. William Blair upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating in a research report on Tuesday. Truist Financial dropped their target price on shares of Genmab A/S from $50.00 to $45.00 and set a “buy” rating for the company in a research report on Tuesday. Finally, BNP Paribas upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 11th.

Institutional Investors Weigh In On Genmab A/S

Several institutional investors have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. grew its position in shares of Genmab A/S by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,891 shares of the company’s stock worth $186,000 after buying an additional 827 shares during the period. EverSource Wealth Advisors LLC grew its position in shares of Genmab A/S by 295.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock worth $26,000 after buying an additional 939 shares during the period. Lindbrook Capital LLC grew its position in shares of Genmab A/S by 105.4% during the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company’s stock worth $39,000 after buying an additional 950 shares during the period. GAMMA Investing LLC grew its position in shares of Genmab A/S by 96.6% during the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock worth $45,000 after buying an additional 1,051 shares during the period. Finally, Eagle Asset Management Inc. grew its position in shares of Genmab A/S by 10.0% during the 3rd quarter. Eagle Asset Management Inc. now owns 12,356 shares of the company’s stock worth $285,000 after buying an additional 1,121 shares during the period. Institutional investors and hedge funds own 7.07% of the company’s stock.

Genmab A/S Stock Performance

NASDAQ:GMAB opened at $20.26 on Wednesday. The company has a 50-day moving average of $21.29 and a 200-day moving average of $22.54. The company has a market capitalization of $13.41 billion, a price-to-earnings ratio of 11.64, a PEG ratio of 2.65 and a beta of 0.98. Genmab A/S has a 52 week low of $18.64 and a 52 week high of $31.88.

Genmab A/S (NASDAQ:GMAB) last announced its earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. Sell-side analysts forecast that Genmab A/S will post 1.45 EPS for the current year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.